Research ExplorerPublicationsPretreatment tables predicting pathologic stage of locally a...

Pretreatment tables predicting pathologic stage of locally advanced prostate cancer

Standard

Pretreatment tables predicting pathologic stage of locally advanced prostate cancer. / Joniau, Steven; Spahn, Martin; Briganti, Alberto; Gandaglia, Giorgio; Tombal, Bertrand; Tosco, Lorenzo; Marchioro, Giansilvio; Hsu, Chao-Yu; Walz, Jochen; Kneitz, Burkhard; Bader, Pia; Frohneberg, Detlef; Tizzani, Alessandro; Graefen, Markus; van Cangh, Paul; Karnes, R Jeffrey; Montorsi, Francesco; van Poppel, Hein; Gontero, Paolo; European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT).

In: EUR UROL, Vol. 67, No. 2, 01.02.2015, p. 319-25.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Joniau, S, Spahn, M, Briganti, A, Gandaglia, G, Tombal, B, Tosco, L, Marchioro, G, Hsu, C-Y, Walz, J, Kneitz, B, Bader, P, Frohneberg, D, Tizzani, A, Graefen, M, van Cangh, P, Karnes, RJ, Montorsi, F, van Poppel, H, Gontero, P & European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT) 2015, 'Pretreatment tables predicting pathologic stage of locally advanced prostate cancer', EUR UROL, vol. 67, no. 2, pp. 319-25. https://doi.org/10.1016/j.eururo.2014.03.013

APA

Joniau, S., Spahn, M., Briganti, A., Gandaglia, G., Tombal, B., Tosco, L., Marchioro, G., Hsu, C-Y., Walz, J., Kneitz, B., Bader, P., Frohneberg, D., Tizzani, A., Graefen, M., van Cangh, P., Karnes, R. J., Montorsi, F., van Poppel, H., Gontero, P., & European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT) (2015). Pretreatment tables predicting pathologic stage of locally advanced prostate cancer. EUR UROL, 67(2), 319-25. https://doi.org/10.1016/j.eururo.2014.03.013

Vancouver

Joniau S, Spahn M, Briganti A, Gandaglia G, Tombal B, Tosco L et al. Pretreatment tables predicting pathologic stage of locally advanced prostate cancer. EUR UROL. 2015 Feb 1;67(2):319-25. https://doi.org/10.1016/j.eururo.2014.03.013

Bibtex

@article{55d16a95c0a2480992031b146d34e1e7,
title = "Pretreatment tables predicting pathologic stage of locally advanced prostate cancer",
abstract = "BACKGROUND: Pretreatment tables for the prediction of pathologic stage have been published and validated for localized prostate cancer (PCa). No such tables are available for locally advanced (cT3a) PCa.OBJECTIVE: To construct tables predicting pathologic outcome after radical prostatectomy (RP) for patients with cT3a PCa with the aim to help guide treatment decisions in clinical practice.DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter retrospective cohort study including 759 consecutive patients with cT3a PCa treated with RP between 1987 and 2010.INTERVENTION: Retropubic RP and pelvic lymphadenectomy.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients were divided into pretreatment prostate-specific antigen (PSA) and biopsy Gleason score (GS) subgroups. These parameters were used to construct tables predicting pathologic outcome and the presence of positive lymph nodes (LNs) after RP for cT3a PCa using ordinal logistic regression.RESULTS AND LIMITATIONS: In the model predicting pathologic outcome, the main effects of biopsy GS and pretreatment PSA were significant. A higher GS and/or higher PSA level was associated with a more unfavorable pathologic outcome. The validation procedure, using a repeated split-sample method, showed good predictive ability. Regression analysis also showed an increasing probability of positive LNs with increasing PSA levels and/or higher GS. Limitations of the study are the retrospective design and the long study period.CONCLUSIONS: These novel tables predict pathologic stage after RP for patients with cT3a PCa based on pretreatment PSA level and biopsy GS. They can be used to guide decision making in men with locally advanced PCa.PATIENT SUMMARY: Our study might provide physicians with a useful tool to predict pathologic stage in locally advanced prostate cancer that might help select patients who may need multimodal treatment.",
author = "Steven Joniau and Martin Spahn and Alberto Briganti and Giorgio Gandaglia and Bertrand Tombal and Lorenzo Tosco and Giansilvio Marchioro and Chao-Yu Hsu and Jochen Walz and Burkhard Kneitz and Pia Bader and Detlef Frohneberg and Alessandro Tizzani and Markus Graefen and {van Cangh}, Paul and Karnes, {R Jeffrey} and Francesco Montorsi and {van Poppel}, Hein and Paolo Gontero and {European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT)}",
note = "Copyright {\textcopyright} 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.",
year = "2015",
month = feb,
day = "1",
doi = "10.1016/j.eururo.2014.03.013",
language = "English",
volume = "67",
pages = "319--25",
journal = "EUR UROL",
issn = "0302-2838",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Pretreatment tables predicting pathologic stage of locally advanced prostate cancer

AU - Joniau, Steven

AU - Spahn, Martin

AU - Briganti, Alberto

AU - Gandaglia, Giorgio

AU - Tombal, Bertrand

AU - Tosco, Lorenzo

AU - Marchioro, Giansilvio

AU - Hsu, Chao-Yu

AU - Walz, Jochen

AU - Kneitz, Burkhard

AU - Bader, Pia

AU - Frohneberg, Detlef

AU - Tizzani, Alessandro

AU - Graefen, Markus

AU - van Cangh, Paul

AU - Karnes, R Jeffrey

AU - Montorsi, Francesco

AU - van Poppel, Hein

AU - Gontero, Paolo

AU - European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT)

N1 - Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - BACKGROUND: Pretreatment tables for the prediction of pathologic stage have been published and validated for localized prostate cancer (PCa). No such tables are available for locally advanced (cT3a) PCa.OBJECTIVE: To construct tables predicting pathologic outcome after radical prostatectomy (RP) for patients with cT3a PCa with the aim to help guide treatment decisions in clinical practice.DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter retrospective cohort study including 759 consecutive patients with cT3a PCa treated with RP between 1987 and 2010.INTERVENTION: Retropubic RP and pelvic lymphadenectomy.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients were divided into pretreatment prostate-specific antigen (PSA) and biopsy Gleason score (GS) subgroups. These parameters were used to construct tables predicting pathologic outcome and the presence of positive lymph nodes (LNs) after RP for cT3a PCa using ordinal logistic regression.RESULTS AND LIMITATIONS: In the model predicting pathologic outcome, the main effects of biopsy GS and pretreatment PSA were significant. A higher GS and/or higher PSA level was associated with a more unfavorable pathologic outcome. The validation procedure, using a repeated split-sample method, showed good predictive ability. Regression analysis also showed an increasing probability of positive LNs with increasing PSA levels and/or higher GS. Limitations of the study are the retrospective design and the long study period.CONCLUSIONS: These novel tables predict pathologic stage after RP for patients with cT3a PCa based on pretreatment PSA level and biopsy GS. They can be used to guide decision making in men with locally advanced PCa.PATIENT SUMMARY: Our study might provide physicians with a useful tool to predict pathologic stage in locally advanced prostate cancer that might help select patients who may need multimodal treatment.

AB - BACKGROUND: Pretreatment tables for the prediction of pathologic stage have been published and validated for localized prostate cancer (PCa). No such tables are available for locally advanced (cT3a) PCa.OBJECTIVE: To construct tables predicting pathologic outcome after radical prostatectomy (RP) for patients with cT3a PCa with the aim to help guide treatment decisions in clinical practice.DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter retrospective cohort study including 759 consecutive patients with cT3a PCa treated with RP between 1987 and 2010.INTERVENTION: Retropubic RP and pelvic lymphadenectomy.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients were divided into pretreatment prostate-specific antigen (PSA) and biopsy Gleason score (GS) subgroups. These parameters were used to construct tables predicting pathologic outcome and the presence of positive lymph nodes (LNs) after RP for cT3a PCa using ordinal logistic regression.RESULTS AND LIMITATIONS: In the model predicting pathologic outcome, the main effects of biopsy GS and pretreatment PSA were significant. A higher GS and/or higher PSA level was associated with a more unfavorable pathologic outcome. The validation procedure, using a repeated split-sample method, showed good predictive ability. Regression analysis also showed an increasing probability of positive LNs with increasing PSA levels and/or higher GS. Limitations of the study are the retrospective design and the long study period.CONCLUSIONS: These novel tables predict pathologic stage after RP for patients with cT3a PCa based on pretreatment PSA level and biopsy GS. They can be used to guide decision making in men with locally advanced PCa.PATIENT SUMMARY: Our study might provide physicians with a useful tool to predict pathologic stage in locally advanced prostate cancer that might help select patients who may need multimodal treatment.

U2 - 10.1016/j.eururo.2014.03.013

DO - 10.1016/j.eururo.2014.03.013

M3 - SCORING: Journal article

C2 - 24684960

VL - 67

SP - 319

EP - 325

JO - EUR UROL

JF - EUR UROL

SN - 0302-2838

IS - 2

ER -